Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Jenny FurlanettoFrederik MarméSibylle LoiblPublished in: Future oncology (London, England) (2022)
Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.
Keyphrases
- phase iii
- positive breast cancer
- open label
- clinical trial
- free survival
- cell surface
- phase ii
- end stage renal disease
- double blind
- squamous cell carcinoma
- small cell lung cancer
- placebo controlled
- chronic kidney disease
- newly diagnosed
- locally advanced
- peritoneal dialysis
- cancer therapy
- rectal cancer
- randomized controlled trial
- patient reported outcomes
- radiation therapy